By Stephen Nakrosis
Shares of Axsome Therapeutics rose post-market after the company received approval for Symbravo from the Food and Drug Administration.
Symbravo, for the acute treatment of migraine with or without aura in adult patients, showed superior efficacy across a broad range of severity, Axsome said Thursday. A single oral dose gave patients rapid relief and allowed a return to normal functioning within two hours, Axsome said.
Axsome's stock was up less than 1% to $109.00 following the market close after touching an all-time high of $111.51 during the regular session. Shares closed the market session up 3.5% at $108.85.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
January 30, 2025 18:59 ET (23:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。